Imdelltra improved survival and high quality of life versus chemotherapy as second-line remedy for small cell lung most cancers, reinforcing it as a brand new SOC.
Amongst sufferers with small cell lung most cancers, second-line remedy with Imdelltra (tarlatamab-dlle) led to statistically vital and clinically significant enhancements in progression-free survival and total survival versus chemotherapy, in response to knowledge from the first evaluation of the section 3 DeLLphi-304 trial offered on the 2025 ASCO Annual Assembly and concurrently printed within the New England Journal of Medication.
Findings confirmed that at a median follow-up of 11.2 months for sufferers handled with Imdelltra (254 sufferers) and 11.7 months for these given chemotherapy (255 sufferers), Imdelltra led to a median total survival of 13.6 months in contrast with 8.3 months for chemotherapy. Within the Imdelltra arm, the 6- and 12-month total survival charges have been 76% and 53%, respectively. These respective charges have been 62% and 37% within the chemotherapy arm.
“Taking the efficacy and security knowledge collectively, these knowledge clearly assist Imdelltra as a preferable remedy for sufferers within the second-line setting for small cell lung most cancers,” lead research writer Dr. Charles M. Rudin stated in a presentation of the information. “Past redefining the usual of look after these sufferers, this research additionally establishes a brand new paradigm for using bispecific, T-cell engager immunotherapies for our sufferers with lung most cancers.”
Rudin is deputy director of the Most cancers Middle, co-director of the Druckenmiller Middle for Lung Most cancers Analysis, and the Sylvia Hassenfeld Chair in Lung Most cancers Analysis at Memorial Sloan Kettering Most cancers Middle in New York, New York.
In Could 2024, the FDA granted accelerated approval to Imdelltra for the remedy of sufferers with extensive-stage small cell lung most cancers with illness development on or after platinum-based chemotherapy. This regulatory choice was supported by knowledge from the section 2 DeLLphi-301 trial.
Extra Efficacy, Affected person-Reported Outcomes and Security Knowledge
Findings additionally demonstrated that the median progression-free survival was 4.2 months for the Imdelltra arm versus 3.7 months for the chemotherapy arm. The 6-month progression-free survival charges within the Imdelltra and chemotherapy arms have been 31% and 23%, respectively; the respective charges at 12 months have been 20% and 4%.
Sufferers within the Imdelltra arm achieved an goal response charge of 35% in contrast with 20% for these given chemotherapy. Within the experimental arm, the charges of full response, partial response, secure illness, and progressive illness have been 1%, 34%, 33% and 22%, respectively. Within the chemotherapy arm, these respective charges have been 0%, 20%, 44% and 20%. Ten % and 16% of sufferers within the Imdelltra and chemotherapy arms, respectively, weren’t evaluable for response.
The median length of response was 6.9 months within the Imdelltra arm in contrast with 5.5 months within the chemotherapy arm. The respective 6- and 12-month length of response charges have been 56% and 41% for Imdelltra in contrast with 29% and 13% for chemotherapy. The median time to response was 1.5 months versus 1.4 months for Imdelltra and chemotherapy, respectively. At knowledge cutoff, response was ongoing in 47% of sufferers within the experimental group versus 15% of the management group.
Concerning patient-reported outcomes, the imply enchancment in dyspnea rating from baseline to week 18 was 1.94 within the Imdelltra arm versus –7.20 within the chemotherapy arm. At week 18, cough rating enhancements have been reported in 16.1% of sufferers within the Imdelltra group versus 9% of sufferers within the management group. Enhancements in chest ache at week 18 have been reported in 8.7% and three.5% of sufferers, respectively.
The median remedy length was 4.2 months within the Imdelltra arm (252 sufferers) versus 2.5 months within the chemotherapy arm (244 sufferers). Any-grade treatment-emergent opposed results occurred in 99% of sufferers within the experimental arm versus all sufferers within the chemotherapy arm. The charges of any-grade treatment-related opposed results have been 93% and 91%, respectively.
Grade 3 (extreme) treatment-related opposed results have been reported in 27% of sufferers within the Imdelltra group in contrast with 62% of sufferers within the chemotherapy group. The respective charges of significant treatment-related opposed results have been 28% and 31%. These results led to dose interruption and/or discount in 19% of sufferers handled with Imdelltra versus 55% given chemotherapy, and led to remedy discontinuation in 3% and 6% of sufferers, respectively. One affected person skilled a grade 5 (loss of life) treatment-related opposed impact within the Imdelltra arm in contrast with 4 sufferers within the chemotherapy arm.
Within the experimental arm, treatment-emergent cytokine launch syndrome occurred in the course of the first 2 cycles of Imdelltra in 60% of sufferers who have been monitored for 48 hours (209 sufferers) at grade 1 (45%), grade 2 (13%), and grade 3 (1%). Nineteen % of sufferers had critical cytokine launch syndrome, and it led to remedy discontinuation in 0.5% of sufferers. The median time to intervention was 27 hours from the final Imdelltra dose.
In sufferers who have been monitored for cytokine launch syndrome for a minimum of six to eight hours in the course of the first 2 cycles of remedy with Imdelltra (43 sufferers), cytokine launch syndrome was reported in 37% of sufferers at grade 1 (28%) and in 9% of sufferers at grade 2. Seven % of situations on this group have been critical, though none led to remedy discontinuation. The median time to intervention was 17 hours.
Though treatment-emergent opposed results reminiscent of cytokine launch syndrome, dysgeusia, fever, and decreased urge for food have been extra widespread with Imdelltra, chemotherapy was related to elevated incidence of anemia, neutropenia, thrombocytopenia, and decreased platelet counts. The charges of grade 3 or larger opposed results reminiscent of anemia, neutropenia, leukopenia, thrombocytopenia, febrile neutropenia, decreased platelet depend, decreased neutrophil depend, fatigue, pneumonia and low sodium ranges have been all larger with chemotherapy versus Imdelltra.
DeLLphi-304 Background
The open-label, randomized, managed research enrolled sufferers a minimum of 18 years of age with histologically or cytologically confirmed small cell lung most cancers who skilled illness development following a first-line, platinum-based routine with or with out an immune checkpoint inhibitor. Sufferers have been required to have an ECOG efficiency standing of 0 or 1. Sufferers with asymptomatic, beforehand handled or untreated mind metastases have been allowed to enroll.
Investigators randomly assigned sufferers in a 1:1 style to obtain Imdelltra or chemotherapy comprising lurbinectedin (47 sufferers), topotecan (185 sufferers), or amrubicin (23 sufferers). Stratification elements included prior remedy with a PD-(L)1 inhibitor (sure versus no), chemotherapy-free interval (lower than 90 days versus a minimum of 90 days to lower than 180 days versus a minimum of 180 days), mind metastases (sure versus no), and supposed chemotherapy (topotecan/amrubicin versus lurbinectedin).
Total survival served because the trial’s main finish level. Development-free survival and patient-reported outcomes have been key secondary finish factors. Different secondary aims included goal response charge, length of response, illness management charge and security.
At baseline, the median age was 64 years within the Imdelltra arm versus 66 years (vary, 26-84) within the chemotherapy arm. Nearly all of sufferers in each arms have been male (Imdelltra, 72%; chemotherapy, 66%), have been White (60%; 55%), have been present or former people who smoke (91%; 88%), had an ECOG efficiency standing of 1 (67%; 68%), obtained prior anti–PD-(L)1 remedy (71%; 71%), and obtained prior radiotherapy (63%; 63%). A chemotherapy-free interval of lower than 90 days was commonest in each arms (43%; 45%), adopted by a minimum of 90 days and fewer than 180 days (33%; 31%) and a minimum of 180 days (24%; 25%).
Mind metastases have been current in 44% of sufferers within the Imdelltra arm versus 45% of sufferers within the chemotherapy arm. The charges of sufferers with liver metastases have been 33% and 37%, respectively. Amongst evaluable sufferers, 95% within the Imdelltra arm (217 sufferers) and 93% within the chemotherapy arm (214 sufferers) have been constructive for DLL3 expression.
Reference:
“Tarlatamab versus chemotherapy as second-line remedy for small cell lung most cancers: main evaluation” by Dr. Charles Rudin, et al., Journal of Medical Oncology.Mountzios G, Solar L, Cho BC, et al. Tarlatamab in small-cell lung most cancers after platinum-based chemotherapy. N Engl J Med. Printed on-line June 2, 2025. doi:10.1056/NEJMoa2502099
For extra information on most cancers updates, analysis and training, don’t overlook to subscribe to CURE®’s newsletters right here.
